TSG101
Ensembl | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| UniProt | |||||||||
| RefSeq (mRNA) | |||||||||
| RefSeq (protein) | |||||||||
| Location (UCSC) | Chr 11: 18.47 – 18.53 Mb | Chr 7: 46.54 – 46.57 Mb | |||||||
| PubMed search | [3] | [4] | |||||||
| View/Edit Human | View/Edit Mouse |
Tumor susceptibility gene 101, also known as TSG101, is a human gene that encodes for a cellular protein of the same name.
Function
The protein encoded by this gene belongs to a group of apparently inactive homologs of ubiquitin-conjugating enzymes. The gene product contains a coiled-coil domain that interacts with stathmin, a cytosolic phosphoprotein implicated in tumorigenesis. The protein may play a role in cell growth and differentiation and act as a negative growth regulator. In vitro steady-state expression of this tumor susceptibility gene appears to be important for maintenance of genomic stability and cell cycle regulation. Mutations and alternative splicing in this gene occur in high frequency in breast cancer and suggest that defects occur during breast cancer tumorigenesis and/or progression.[5]
The main role of TSG101 is to participate in
Viral Hijacking
TSG101 plays an important role in the pathogenesis of
Interactions
TSG101 has been shown to
Orthologue, Vps23
| Vps23_core | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 escrt-i core | |||||||||
| Identifiers | |||||||||
| Symbol | Vps23_core | ||||||||
| Pfam | PF09454 | ||||||||
| InterPro | IPR017916 | ||||||||
| |||||||||
In humans, the orthologue of vps23 which has a component of ESCRT-1 is called Tsg101. Mutations in Tsg-101 have been linked to cervical, breast, prostate and gastrointestinal cancers. In molecular biology, vps23 (vacuolar protein sorting) is a protein domain. Vps proteins are components of the ESCRTs (endosomal sorting complexes required for transport) which are required for protein sorting at the early endosome. More specifically, vps23 is a component of ESCRT-I. The ESCRT complexes form the machinery driving protein sorting from endosomes to lysosomes. ESCRT complexes are central to receptor down-regulation, lysosome biogenesis and budding of HIV.
Structure
See also
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000074319 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000014402 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Entrez Gene: TSG101 tumor susceptibility gene 101".
- PMID 21763610.
- S2CID 14017291.
- PMID 16615894.
- S2CID 1344520.
- S2CID 16894972.
- S2CID 26971556.
- ^ S2CID 4427026.
- PMID 12802020.
- PMID 15256501.
- PMID 11943869.
- PMID 11172000.
- PMID 15218037.
- PMID 11134028.
Further reading
- Mazzé FM, Degrève L (2006). "The role of viral and cellular proteins in the budding of human immunodeficiency virus". Acta Virol. 50 (2): 75–85. PMID 16808324.
- Freed EO, Mouland AJ (2006). "The cell biology of HIV-1 and other retroviruses". Retrovirology. 3: 77. PMID 17083721.
- Li L, Li X, Francke U, Cohen SN (1997). "The TSG101 tumor susceptibility gene is located in chromosome 11 band p15 and is mutated in human breast cancer". Cell. 88 (1): 143–54. PMID 9019400.
- Koonin EV, Abagyan RA (1997). "TSG101 may be the prototype of a class of dominant negative ubiquitin regulators". Nat. Genet. 16 (4): 330–1. S2CID 36275138.
- Steiner P, Barnes DM, Harris WH, Weinberg RA (1997). "Absence of rearrangements in the tumour susceptibility gene TSG101 in human breast cancer". Nat. Genet. 16 (4): 332–3. S2CID 20233125.
- Lee MP, Feinberg AP (1997). "Aberrant splicing but not mutations of TSG101 in human breast cancer". Cancer Res. 57 (15): 3131–4. PMID 9242438.
- Gayther SA, Barski P, Batley SJ, Li L, de Foy KA, Cohen SN, Ponder BA, Caldas C (1997). "Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours". Oncogene. 15 (17): 2119–26. S2CID 7819803.
- Xie W, Li L, Cohen SN (1998). "Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency". Proc. Natl. Acad. Sci. U.S.A. 95 (4): 1595–600. PMID 9465061.
- Wagner KU, Dierisseau P, Rucker EB, Robinson GW, Hennighausen L (1998). "Genomic architecture and transcriptional activation of the mouse and human tumor susceptibility gene TSG101: common types of shorter transcripts are true alternative splice variants". Oncogene. 17 (21): 2761–70. S2CID 29505462.
- Sun Z, Pan J, Hope WX, Cohen SN, Balk SP (1999). "Tumor susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300". Cancer. 86 (4): 689–96. S2CID 26971556.
- Hittelman AB, Burakov D, Iñiguez-Lluhí JA, Freedman LP, Garabedian MJ (1999). "Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins". EMBO J. 18 (19): 5380–8. PMID 10508170.
- Rountree MR, Bachman KE, Baylin SB (2000). "DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci". Nat. Genet. 25 (3): 269–77. S2CID 26149386.
- Bishop N, Woodman P (2001). "TSG101/mammalian VPS23 and mammalian VPS28 interact directly and are recruited to VPS4-induced endosomes". J. Biol. Chem. 276 (15): 11735–42. PMID 11134028.
- Li L, Liao J, Ruland J, Mak TW, Cohen SN (2001). "A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control". Proc. Natl. Acad. Sci. U.S.A. 98 (4): 1619–24. PMID 11172000.
- VerPlank L, Bouamr F, LaGrassa TJ, Agresta B, Kikonyogo A, Leis J, Carter CA (2001). "Tsg101, a homologue of ubiquitin-conjugating (E2) enzymes, binds the L domain in HIV type 1 Pr55(Gag)". Proc. Natl. Acad. Sci. U.S.A. 98 (14): 7724–9. PMID 11427703.
- Garrus JE, von Schwedler UK, Pornillos OW, Morham SG, Zavitz KH, Wang HE, Wettstein DA, Stray KM, Côté M, Rich RL, Myszka DG, Sundquist WI (2001). "Tsg101 and the vacuolar protein sorting pathway are essential for HIV-1 budding". Cell. 107 (1): 55–65. S2CID 18525780.
- Martin-Serrano J, Zang T, S2CID 19655035.
- Demirov DG, Ono A, Orenstein JM, Freed EO (2002). "Overexpression of the N-terminal domain of TSG101 inhibits HIV-1 budding by blocking late domain function". Proc. Natl. Acad. Sci. U.S.A. 99 (2): 955–60. PMID 11805336.
- Bennett NA, Pattillo RA, Lin RS, Hsieh CY, Murphy T, Lyn D (2002). "TSG101 expression in gynecological tumors: relationship to cyclin D1, cyclin E, p53 and p16 proteins". Cell. Mol. Biol. (Noisy-le-grand). 47 (7): 1187–93. PMID 11838966.
- Bishop N, Horman A, Woodman P (2002). "Mammalian class E vps proteins recognize ubiquitin and act in the removal of endosomal protein-ubiquitin conjugates". J. Cell Biol. 157 (1): 91–101. PMID 11916981.
PDB gallery | |
|---|---|
|
